Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIT-001 for prevention of oral mucositis during chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
KCT0006251Phase 2Recruiting
- Sponsor
- MitoImmune Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing MIT-001 with Placebo (2 arms). Started May 2022; status: recruiting.
02
Drugs
LC28-0126
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on KCT0006251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006251.